Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors

Documenti analoghi

• Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models()()
  di: Van Looy, Thomas, et al.
  Pubblicazione: (2015)
• Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models()()()
  di: Li, Haifu, et al.
  Pubblicazione: (2014)
• Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors
  di: Yannick Wang, et al.
  Pubblicazione: (2020-11-01)
• Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors
  di: Wang, Yannick, et al.
  Pubblicazione: (2020)
• Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts
  di: Cornillie, Jasmien, et al.
  Pubblicazione: (2019)